Degeneration and recovery of the neuromuscular junction after application of extracorporeal shock wave therapy

Journal of Orthopaedic Research

Volumn 30, Issue 10, 2012, Pages 1660-1665

  Kenmoku, Tomonori ^a   Ochiai, Nobuyasu ^a   Ohtori, Seiji ^a   Saisu, Takashi ^b   Sasho, Takahisa ^a   Nakagawa, Koichi ^a   Iwakura, Nahoko ^a   Miyagi, Masayuki ^a   Ishikawa, Tetsuhiro ^a   Tatsuoka, Hodumi ^a   Inoue, Gen ^a   Nakamura, Junichi ^a   Kishida, Shunji ^a   Saito, Atsushi ^a   Takahashi, Kazuhisa ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA CHILDREN'S HOSPITAL   (Japan)

Author keywords

acetylcholine receptor; compound muscle action potential; extracorporeal shock wave therapy; neuromuscular junction; neuromuscular transmission

Indexed keywords

ALPHA BUNGAROTOXIN; RHODAMINE;

ARTICLE; DEGENERATIVE DISEASE; EXTRACORPOREAL SHOCK WAVE THERAPY; GASTROCNEMIUS MUSCLE; MALE; MUSCLE ACTION POTENTIAL; MUSCLE INJURY; NERVE CONDUCTION; NEUROMUSCULAR SYNAPSE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; ULTRASOUND THERAPY;

ANIMALS; DYSTONIA; HIGH-ENERGY SHOCK WAVES; MALE; MUSCLE SPASTICITY; NEUROMUSCULAR JUNCTION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CHOLINERGIC; ULTRASONIC SURGICAL PROCEDURES;

EID: 84865465232     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22111     Document Type: Article

References (14)

1. Mauritz KH., 2002. Gait training in hemiplegia. Eur J Neurol 9: 23-29.
2. Mayer NH, Esquenazi A, Childers MK., 1997. Common patterns of clinical motor dysfunction. Muscle Nerve Suppl 6: S21-S35. (Pubitemid 128753037)
3. Brin MF, Mallett M, Jankovic J, editors. 2002. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams & Wilkins.
4. Koman LA, Mooney JP, Smith BP, et al. 1993. Management of spasticity in cerebral palsy with botulinum toxin A: preliminary investigation. J Pediatr Orthop 13: 489-495. (Pubitemid 23174659)
5. Manganotti P, Amelio E., 2005. Long-term effect of shock wave therapy on upper limb hypertonia in patients affected by stroke. Stroke 36: 1967-1971. (Pubitemid 41266535)
6. Trompetto C, Avanzino L, Bove M, et al. 2009. External shock waves therapy in dystonia: preliminary results. Eur J Neurol 16: 517-521.
7. Ohtori S, Inoue G, Mannoji C, et al. 2001. Shock wave application to rat skin induces degeneration and reinnervation of sensory nerve fibers. Neurosci Lett 315: 57-60. (Pubitemid 33049998)
8. Takahashi N, Ohtori S, Saisu T, et al. 2006. Second application of low-energy shock waves has a cumulative effect on free nerve endings. Clin Orthop Relat Res 443: 315-319. (Pubitemid 44324962)
9. Ma J, Smith BP, Walker FO, et al. 2002. Juvenile and adult rat neuromuscular junctions: density, distribution, and morphology. Muscle Nerve 26: 804-809. (Pubitemid 35424431)
10. Cichon JV Jr, McCaffrey TV, Litchy WJ, et al. 1995. The effect of botulinum toxin type A injection on compound muscle action potential in an in vivo rat model. Laryngoscope 105: 144-148.
11. Kessler KR, Benecke R., 1997. The EDB test-a clinical test for the detection of antibodies to botulinum toxin type A. Mov Disord 12: 95-99. (Pubitemid 27032886)
12. Sakamoto T, Torii Y, Takahashi M, et al. 2009. Quantitative determination of the biological activity of botulinum toxin type A by measuring the compound muscle action potential (CMAP) in rats. Toxicon 54: 857-861.
13. Torii Y, Goto Y, Takahashi M, et al. 2010. Quantitative determination of biological activity of botulinum toxins utilizing compound muscle action potentials (CMAP), and comparison of neuromuscular transmission blockage and muscle flaccidity among toxins. Toxicon 55: 407-414.
14. Karp BI, Cole RA, Cohen LG, et al. 1994. Long-term botulinum toxin treatment of focal hand dystonia. Neurology 44: 70-76. (Pubitemid 24029432)